Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
In order to understand a drug's full profile in the post-marketing environment, information is needed regarding utilization patterns, beneficial effects, ADRs and economic value. China, the most populated country in the world, has the largest number of people who are taking medications. To begin to appreciate the impact of these medications, a multifunctional evaluation and surveillance system was developed, the Shanghai Drug Monitoring and Evaluative System (SDMES). Set up by the Shanghai Center for Adverse Drug Reaction Monitoring in 2001, the SDMES contains three databases: a population health data base of middle aged and elderly persons; hospital patient medical records; and a spontaneous ADR reporting database. Each person has a unique identification and Medicare number, which permits record-linkage within and between these three databases. After more than three years in development, the population health database has comprehensive data for more than 320,000 residents. The hospital database has two years of inpatient medical records from five major hospitals, and will be increasing to 10 hospitals in 2007. The spontaneous reporting ADR database has collected 20,205 cases since 2001 from approximately 295 sources, including hospitals, pharmaceutical companies, drug wholesalers and pharmacies. The SDMES has the potential to become an important national and international pharmacoepidemiology resource for drug evaluation.
Du
Wenmin
W
Shanghai Center for Adverse Drug Reaction Monitoring, Shanghai, China.
Levine
Mitchell
M
Wang
Longxing
L
Zhang
Yaohua
Y
Yi
Chengdong
C
Wang
Hongmin
H
Wang
Xiaoyu
X
Xie
Hongjuan
H
Xu
Jianglong
J
Jin
Huilin
H
Wang
Tongchun
T
Huang
Gan
G
Wu
Ye
Y
D016907:Adverse Drug Reaction Reporting Systems; D002681:China; D019992:Databases as Topic; D011358:Product Surveillance, Postmarketing